Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $11.00

Humacyte (NASDAQ:HUMA) had its price objective decreased by analysts at Benchmark from $14.00 to $11.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock.

HUMA has been the subject of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Humacyte in a report on Wednesday, October 8th. HC Wainwright dropped their target price on Humacyte from $4.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, August 12th. UBS Group set a $6.00 price objective on shares of Humacyte in a research note on Monday, October 13th. TD Cowen dropped their target price on shares of Humacyte from $5.00 to $3.50 and set a “buy” rating on the stock in a research report on Tuesday, August 12th. Finally, Barclays assumed coverage on shares of Humacyte in a report on Wednesday, August 27th. They set an “overweight” rating and a $3.50 target price for the company. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Humacyte currently has an average rating of “Moderate Buy” and an average price target of $8.29.

Humacyte Price Performance

Humacyte stock traded down $0.07 during mid-day trading on Thursday, reaching $1.19. 5,600,245 shares of the company were exchanged, compared to its average volume of 4,305,294. The company has a fifty day simple moving average of $1.64 and a 200-day simple moving average of $1.95. The firm has a market cap of $187.67 million, a PE ratio of -2.63 and a beta of 1.88. The company has a debt-to-equity ratio of 2.97, a current ratio of 2.45 and a quick ratio of 1.93. Humacyte has a 12 month low of $1.15 and a 12 month high of $6.77.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.92 million. As a group, equities research analysts expect that Humacyte will post -1.27 earnings per share for the current fiscal year.

Insider Activity at Humacyte

In related news, Director Brady W. Dougan sold 1,100,000 shares of Humacyte stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $1.63, for a total transaction of $1,793,000.00. Following the transaction, the director owned 591,685 shares in the company, valued at approximately $964,446.55. The trade was a 65.02% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Laura E. Niklason sold 1,100,000 shares of the business’s stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $1.63, for a total value of $1,793,000.00. Following the completion of the transaction, the chief executive officer owned 591,685 shares in the company, valued at approximately $964,446.55. This trade represents a 65.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,482,090 shares of company stock worth $7,466,382 in the last 90 days. 5.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Humacyte

Several hedge funds have recently bought and sold shares of HUMA. Monashee Investment Management LLC acquired a new stake in shares of Humacyte during the 1st quarter valued at $3,410,000. Polar Asset Management Partners Inc. acquired a new position in Humacyte in the 1st quarter worth about $852,000. Woodline Partners LP raised its stake in shares of Humacyte by 38.7% during the 1st quarter. Woodline Partners LP now owns 3,950,000 shares of the company’s stock worth $6,735,000 after purchasing an additional 1,101,198 shares in the last quarter. Nuveen LLC bought a new stake in shares of Humacyte in the 1st quarter valued at approximately $502,000. Finally, Pamalican Asset Management Ltd acquired a new position in Humacyte in the first quarter worth approximately $341,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.